Antidotes and poisoning medical products, part 2 / 2024-2025

Finnish Institue for Health and Welfare

Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in nine (9) lots. Tender may be submitted for one or several lots. - LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - LOT 3: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - LOT 4: Physostigmine 2 mg/5 ml (5 ml per vial/ampoule, ATC V03AB19) - LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13) - LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) All products are for CBRN poisoning treatment or CBRN antidotes. The minimum requirements for the articles is described in Annex 1.1. The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed. Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the Articles under the Option. Please note that all times given in the Call for Tenders refer to local time in Finland. Call for Tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 Description of the Handi service Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Estimated quantity (restricted, TL IV) Annex 7 Confidentiality commitment Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.

Määräaika

Tarjousten vastaanottamisen määräaika oli 2024-02-26. Hankinta julkaistiin 2024-01-22.

Kuka? Mitä? Missä?
Hankintojen historia
Päivämäärä Asiakirja
2024-01-22 hankintailmoitus
2024-02-08 hankintailmoitus
hankintailmoitus (2024-01-22)
Kohde
Hankinnan laajuus
Otsikko: Antidotes and poisoning medical products, part 2 / 2024-2025
Viitenumero: THL/236/2.02.06/2024
Lyhyt kuvaus:
Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in nine (9) lots. Tender may be submitted for one or several lots. - LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - LOT 3: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - LOT 4: Physostigmine 2 mg/5 ml (5 ml per vial/ampoule, ATC V03AB19) - LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13) - LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) All products are for CBRN poisoning treatment or CBRN antidotes. The minimum requirements for the articles is described in Annex 1.1. The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed. Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the Articles under the Option. Please note that all times given in the Call for Tenders refer to local time in Finland. Call for Tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 Description of the Handi service Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Estimated quantity (restricted, TL IV) Annex 7 Confidentiality commitment Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.
Näytä lisää
Sopimustyyppi: Tavarat
Tuotteet/palvelut: Muut lääkkeet 📦
Tietoa eristä
Tämä sopimus on jaettu osiin ✅
Yhdelle tarjoajalle myönnettävien erien enimmäismäärä: 9
Tarjouksia voidaan jättää enintään yhtä erää varten: 9

1️⃣
Sisäinen tunniste: 1
Otsikko: LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - Parenteral products (intramuscular administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Strength: 1 mg/ml - Pharmaceutical form: pre-filled syringe The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Lisätuotteet/palvelut: Farmaseuttiset tuotteet 📦
Kesto: 17 kuukautta
Tietoa vaihtoehdoista
Vaihtoehdot ✅
Vaihtoehtojen kuvaus:
In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
Näytä lisää
Myöntämisperusteet
Hinta ✅
Laatukriteeri (nimi): Quality 1: Registered shelf life of the product
Quality 2: Delivery time to the customer’s warehouse
Quality 3: Language of packaging and product information leaflet
Quality 4: Transportation temperature and excursions
Quality 5: EMA centralized EU Marketing Authorisation for the product
Otsikko
Erän tunnistenumero: LOT-0001

2️⃣
Sisäinen tunniste: 2
Otsikko: LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Strength: 0,4 mg/ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0002

3️⃣
Sisäinen tunniste: 3
Otsikko: LOT 3: Sodiumthiosulfate 25 % / 100 ml (100 ml per vial/ampule, ATC V03AB06)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Sodiumthiosulfate - Strength: 25 % / 100 ml - Pharmaceutical form: vial/ampule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0003

4️⃣
Sisäinen tunniste: 4
Otsikko: LOT 4: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Physostigmine - Strength: 2 mg / 5 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0004

5️⃣
Sisäinen tunniste: 5
Otsikko: LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Ethanol - Strength: 95 – 96 % / 20 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0005

6️⃣
Sisäinen tunniste: 6
Otsikko: LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Silibinin - Pharmaceutical form: powder for i.v. / vial The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0006

7️⃣
Sisäinen tunniste: 7
Otsikko: LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Atropine sulphate - Strength: 10 mg/ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0007

8️⃣
Sisäinen tunniste: 8
Otsikko: LOT 8: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13) - Parenteral products (sub-cutaneous) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Pegfilgrastim - Strength: 6 mg / 0,6 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0008

9️⃣
Sisäinen tunniste: 9
Otsikko: LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) - Solutions for nasal use for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Pharmaceutical form: single dose container (no further device assembly is required) The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Otsikko
Erän tunnistenumero: LOT-0009

Menettely
Toimenpiteen tyyppi
Avoin menettely ✅
Oikeusperusta: Direktiivi 2014/24/EU
Menettelyn tärkeimmät piirteet:
Tenders must be submitted electronically via the Cloudia Supplier Portal. It is the responsibility of the tenderer to submit the tender by the deadline. No compensation will be paid for submitting a tender. Requirements concerning tenderers and the article, as well as eventual reports and explanations required in the tender, are described in this Call for Tenders. All the attachments mentioned in the Call for Tenders should be sent with the tender. The tender must be submitted in writing, in English. Also, the annexes and all related material or correspondence must be in English. The process steps are: 1. Opening the tenders. 2. Inspecting the suitability of tenderers according to the ESPD form. 3. Inspecting that tenders meet the requirements set in the Call for Tender. 4. Comparison of tenders. 5. Making and announcing the contract award decision. 6. Verifying the information given by the awarded tenderer on the ESPD form. 7. Background check by asking the winning tenderer to submit criminal record excerpts. 8. Drafting the procurement contract. A procurement contract is only valid after a written agreement is signed. The procurement contract can be signed no earlier than 14 days from the time the tenderer has been informed, or is considered to have been informed, of the contract award decision and its grounds (=stand-still period).
Näytä lisää
Hallinnolliset tiedot
Tarjousten tai osallistumishakemusten vastaanottamisen määräaika: 2024-02-26 12:00:00 📅
Tarjousten avaamista koskevat ehdot: 2024-02-26 12:30:00 📅
Kielet, joilla tarjoukset tai osallistumishakemukset voidaan jättää: englanti 🗣️
Vähimmäisaika, jonka kuluessa tarjoajan on pidettävä tarjous voimassa: 6 kuukautta
Tarjouspyynnön ehdot
Tarjoaja voi jättää useamman kuin yhden tarjouksen
Tarjousten avaamisen päivämäärä: 2024-02-26 12:30:00 📅
Sähköinen laskutus: Pakollinen
Sähköistä tilaamista käytetään ✅
Sähköistä maksua käytetään ✅
Lisätietojen pyytämisen määräaika: 2024-02-12 16:00:00 📅
Sopimukseen sisältyy suoritusehtoja ✅
Salassapitosopimus on pakollinen ✅

Oikeudelliset, taloudelliset, rahoitukselliset ja tekniset tiedot
Taloudellinen ja rahoituksellinen asema
Luettelo ja lyhyt kuvaus valintaperusteista:
Yearly turnover: Its (“general”) yearly turnover is as follows: Year 2022: 1000000,00 EUR Year 2021: 1000000,00 EUR
Osallistumisehdot
Luettelo ja lyhyt kuvaus olosuhteista:
Enrolment in a relevant professional register: It is enrolled in the relevant professional registers kept in the Member State of its establishment.
Enrolment in a trade register: It is enrolled in the relevant trade registers kept in the Member State of its establishment.
Sopimukseen liittyvät ehdot
Sopimuksen täytäntöönpanoehdot: For further details please see the documents of the Call for Tenders.
Osallistumisehdot
Poissulkemisperuste:
Ennenaikainen irtisanominen, vahingonkorvaukset tai muut vastaavat seuraamukset
Järjestelyt velkojien kanssa
Kansallisesta lainsäädännöstä johtuva konkurssia tai muuta sellaista vastaava tilanne
+ 21 lisää
Konkurssi
Korruptio
Lapsityövoima ja muut ihmiskaupan muodot
Liiketoiminta on keskeytetty
Maksukyvyttömyys
Petos
Puhtaasti kansalliset poissulkemisperusteet
Rahanpesu tai terrorismin rahoitus
Rikollisjärjestön toimintaan osallistuminen
Sosiaalilainsäädännön mukaisten velvoitteiden rikkominen
Sosiaaliturvamaksujen maksaminen
Syyllistyminen ammatin harjoittamiseen liittyvään vakavaan virheeseen
Syyllistyminen väärien tietojen antamiseen, tietojen antamatta jättämiseen, vaadittujen asiakirjojen antamiseen kykenemättömien tietojen toimittamiseen ja tätä menettelyä koskevien luottamuksellisten tietojen antamiseen
Talouden toimijan hankintamenettelyyn osallistumisesta johtuvat eturistiriidat
Terrorismirikokset tai terroritoimintaan liittyvät rikokset
Toisten talouden toimijoiden kanssa kilpailun vääristämiseksi tehdyt sopimukset
Työlainsäädännön mukaisten velvoitteiden rikkominen
Varat selvitysmiehen hallinnassa
Verojen maksu
Välitön tai välillinen osallistuminen tämän hankintamenettelyn valmisteluun
Ympäristölainsäädännön mukaisten velvoitteiden rikkominen
Kuvaus poissulkemisperusteista:
The economic operator is in any analogous situation like bankruptcy arising from a similar procedure under national laws and regulations.
The economic operator is bankrupt.
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for corruption, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
Näytä lisää
The economic operator is in arrangement with creditors.
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for participation in a criminal organisation, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
Näytä lisää
The economic operator has entered into agreements with other economic operators aimed at distorting competition.
The economic operator has breached its obligations in the field of environmental law.
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for…
… money laundering or terrorist financing, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
… fraud, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
… child labour and other forms of trafficking in human beings, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
The economic operator is the subject of insolvency or winding-up.
The economic operator has breached its obligations in the field of labour law.
The assets of the economic operator are being administered by a liquidator or by the court.
The economic operator can confirm that: a) It has been guilty of serious misrepresentation in supplying the information required for the verification of the absence of grounds for exclusion or the fulfilment of the selection criteria, b) It has withheld such information, c) It has not been able, without delay, to submit the supporting documents required by a contracting authority or contracting entity, and d) It has undertaken to unduly influence the decision making process of the contracting authority or contracting entity, to obtain confidential information that may confer upon it undue advantages in the procurement procedure or to negligently provide misleading information that may have a material influence on decisions concerning exclusion, selection or award.
Näytä lisää
Any person who is a member of the economic operator’s administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for work safety offence, working hours offence, work discrimination, extortionate work discrimination, violation of the right to organise or unauthorised use of foreign labour.
Näytä lisää
The economic operator is aware of any conflict of interest, as indicated in national law, the relevant notice or the procurement documents due to its participation in the procurement procedure.
The economic operator or an undertaking related to it has advised the contracting authority or contracting entity or otherwise been involved in the preparation of the procurement procedure.
The economic operator is guilty of grave professional misconduct.
The economic operator has experienced that a prior public contract, a prior contract with a contracting entity or a prior concession contract was terminated early, or that damages or other comparable sanctions were imposed in connection with that prior contract.
Näytä lisää
The economic operator has breached its obligations in the field of social law.
The economic operator has breached its obligations relating to the payment social security contributions, both in the country in which it is established and in Member State of the contracting authority or contracting entity if other than the country of establishment.
Näytä lisää
The business activities of the economic operator are suspended.
The economic operator has breached its obligations relating to the payment of taxes, both in the country in which it is established and in Member State of the contracting authority or contracting entity if other than the country of establishment.
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for terrorist offences or offences linked to terrorist activities, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
Näytä lisää

Hankintaviranomainen
Nimi ja osoitteet
Nimi: Finnish Institue for Health and Welfare
Kansallinen rekisterinumero: 2229500-6
Postiosoite: P. O. BOX 30
Postinumero: 00271
Postitoimipaikka: Helsinki
Alue: Helsinki-Uusimaa 🏙️
Maa: Suomi 🇫🇮
Yhteyspiste: Henri Tenhunen
Sähköposti: henri.tenhunen@thl.fi 📧
Puhelin: +358 295246000 📞
URL: https://thl.fi/en/web/thlfi-en 🌏
Hankintaviranomaisen tyyppi
Ministeriö tai muu kansallinen tai liittovaltiotason viranomainen
Päätoimi
Terveys
Viestintä
Osallistumisen URL-osoite: https://tarjouspalvelu.fi/thl?id=491843&tpk=16881245-1076-4741-a3d8-098a8bb71ebd 🌏
EU:n rahoituksen tunniste: rescEU-CBRNSTOCK-FI
Lisätietoa EU-rahoituksesta: rescEU - CBRN Stockpiling in Finland
EU:n rahoitusohjelma: Unionin pelastuspalvelumekanismi (rescEU) (2021/2027)
Perustelut tiettyjen hankinta-asiakirjojen saatavuuden rajoittamiselle: Erityisen arkaluonteisten tietojen suojaaminen
Hankinta-asiakirjoihin pääsyä on rajoitettu
Hankinta-asiakirjan kieli: englanti 🗣️
Tarjouksen/hakemuksen jättäminen sähköisesti: Pakollinen

Täydentävät tiedot
Lisätietoja
The availability for the Annex 6 is restricted to security classification level IV, TL IV. THL will send the restricted Annex 6 to a representative of the tenderer via encrypted email after THL has received the signed confidentiality commitment (Annex 7). Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/236/2.02.06/2024 / Antidotes and poisoning medical products, part 2". The message shall contain name of the tenderer and email address to which the restricted Annex 6 is to be sent.
Näytä lisää
Arvostelurunko
Nimi: Markkinaoikeus
Kansallinen rekisterinumero: 3006157-6
Postiosoite: Radanrakentajantie 5
Postinumero: 00520
Postitoimipaikka: Helsinki
Alue: Helsinki-Uusimaa 🏙️
Maa: Suomi 🇫🇮
Sähköposti: markkinaoikeus@oikeus.fi 📧
Puhelin: +358 295643300 📞
URL: http://www.oikeus.fi/markkinaoikeus 🌏
Tietoa sähköisistä työnkuluista
Sähköinen laskutus hyväksytään
Lähde: OJS 2024/S 017-048903 (2024-01-22)
hankintailmoitus (2024-02-08)
Kohde
Hankinnan laajuus
Lyhyt kuvaus:
Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in nine (9) lots. Tender may be submitted for one or several lots. - LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - LOT 3: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - LOT 4: Physostigmine 2 mg/5 ml (5 ml per vial/ampoule, ATC V03AB19) - LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13) - LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) All products are for CBRN poisoning treatment or CBRN antidotes. The minimum requirements for the articles is described in Annex 1.1. The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed. Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the Articles under the Option. Please note that all times given in the Call for Tenders refer to local time in Finland. Call for Tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 Description of the Handi service Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Estimated quantity (restricted, TL IV) Annex 7 Confidentiality commitment Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.
Näytä lisää
Kuvaus
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender:…
… Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - Parenteral products (intramuscular administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Strength: 1 mg/ml - Pharmaceutical form: pre-filled syringe The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
… Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Strength: 0,4 mg/ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
… Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Sodiumthiosulfate - Strength: 25 % / 100 ml - Pharmaceutical form: vial/ampule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
… Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Physostigmine - Strength: 2 mg / 5 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
… Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Ethanol - Strength: 95 – 96 % / 20 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
… Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Silibinin - Pharmaceutical form: powder for i.v. / vial The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
… Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Atropine sulphate - Strength: 10 mg/ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Otsikko: LOT 8: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13)
Hankinnan kuvaus:
The subject of the procurement is article in accordance with the following requirements: - The subject of tender:…
… Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13) - Parenteral products (sub-cutaneous) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Pegfilgrastim - Strength: 6 mg / 0,6 ml - Pharmaceutical form: vial/ampoule/prefilled syringe The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
… Naloxone / single dose container (no further device assembly is required, ATC V03AB15) - Solutions for nasal use for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Pharmaceutical form: single dose container (no further device assembly is required) The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.

Menettely
Toimenpiteen tyyppi
Menettelyn tärkeimmät piirteet:
Tenders must be submitted electronically via the Cloudia Supplier Portal. It is the responsibility of the tenderer to submit the tender by the deadline. No compensation will be paid for submitting a tender. Requirements concerning tenderers and the article, as well as eventual reports and explanations required in the tender, are described in this Call for Tenders. All the attachments mentioned in the Call for Tenders should be sent with the tender. The tender must be submitted in writing, in English. Also, the annexes and all related material or correspondence must be in English. The process steps are: 1. Opening the tenders. 2. Inspecting the suitability of tenderers according to the ESPD form. 3. Inspecting that tenders meet the requirements set in the Call for Tender. 4. Comparison of tenders. 5. Making and announcing the contract award decision. 6. Verifying the information given by the awarded tenderer on the ESPD form. 7. Background check by asking the winning tenderer to submit criminal record excerpts. 8. Drafting the procurement contract. A procurement contract is only valid after a written agreement is signed. The procurement contract can be signed no earlier than 14 days from the time the tenderer has been informed, or is considered to have been informed, of the contract award decision and its grounds (=stand-still period).
Näytä lisää
Tarjouspyynnön ehdot
Lisätietojen pyytämisen määräaika: 2024-02-14 12:00:00 📅

Muutokset
Alkuperäiseen ilmoitukseen korjattava teksti
Jakson numero: PROCEDURE
Erän tunnistenumero: LOT-0001
LOT-0002
LOT-0003
LOT-0004
LOT-0005
LOT-0006
LOT-0007
LOT-0008
LOT-0009
Muut lisätiedot
In the case of "LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13)", the pharmaceutical form "prefilled syringe" has not been indicated in the original Call for tenders. Prefilled syringe is also an acceptable pharmaceutical form for LOT 8, which is why it has been added to the Call for tenders. The procurement documents have been amended to reflect this change. The deadline for submitting additional questions has been extended until 14/02/2024, 12:00 (GMT+2).
Näytä lisää
Muutoksen pääasiallinen syy: Julkaisijan virheen korjaaminen
Tiedot muutoksista
Muutettavan ilmoituksen edellinen versio: 6a3a9b60-dbc9-4927-a3f7-a1de1e898578-01
Lähde: OJS 2024/S 029-086075 (2024-02-08)
Uudet hankinnat asiaan liittyvissä luokissa 🆕
Aiheeseen liittyvät haut 🔍
Alue:
Suomi/Finland Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Tuotteet/palvelut:
Lääketieteelliset laitteet,... Farmaseuttiset tuotteet Muut lääkkeet